Plasma level of soluble c-Met is tightly associated with the clinical risk of preeclampsia.
OBJECTIVE
The objective of the study was to examine the relevance of the soluble form c-Met (sMet) with the clinical risk for severe preeclampsia.


METHODS
This prospective case-control study was performed by using plasma derived from 44 preeclamptic and 51 uncomplicated pregnant women. Plasma concentration of sMet was measured with specific enzyme-linked immunosorbent assay, and the predictive values were determined based on the receiver-operating characteristic (ROC) curves analysis.


RESULTS
Plasma s-Met level in normal pregnant women changed in a gestation-dependent manner, peaking at weeks 19-24. In women with severe preeclampsia, the circulating sMet level was significantly lower than that in the gestational stage-matched controls during gestational weeks 15-30. The ROC curve analysis revealed a significant correlation between plasma sMet level and the risk of developing severe preeclampsia.


CONCLUSIONS
Plasma sMet could serve as a potential biomarker for predicting severe preeclampia at early second trimester of pregnancy.
Zeng
Xin
X
State Key Laboratory of Reproductive Biology, Institute of Zoology, Graduate School, Chinese Academy of Sciences, and Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China.
Sun
Yu
Y
Yang
Hui-xia
HX
Li
Dong
D
Li
Yu-xia
YX
Liao
Qin-ping
QP
Wang
Yan-ling
YL
D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D011225:Pre-Eclampsia / Q000097:blood*; D011237:Predictive Value of Tests; D011247:Pregnancy; D011446:Prospective Studies; D019859:Proto-Oncogene Proteins c-met / Q000097:blood*; D012307:Risk Factors
D019859:Proto-Oncogene Proteins c-met